Boehringer Ingelheim To Channel €100 Million Into Shanghai To Expand Production, Strengthen Quality Controls On APIs From China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Germany's Boehringer Ingelheim recently announced it would funnel a new €100 million ($ 150 million) investment into China to increase production capacity at its plant in the Shanghai Zhangjiang Hi-Tech Park and to introduce state-of-the-art quality control technology for active pharmaceutical ingredients sourced from China
You may also be interested in...
Where’s The Beef? China Pushes For More Stringent Controls On Veterinary Drugs
A draft proposal by the Ministry of Agriculture comes at a time when several Big Pharma are pursuing opportunities in China’s veterinary market.
Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List
SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China
Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List
SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China